Brand Intelligence Graphcompany
Company Overview
About Regeneron Pharmaceuticals
Regeneron Pharmaceuticals, Inc. is a leading biotechnology company specializing in the discovery, development, and commercialization of medicines for serious diseases, headquartered in Tarrytown, New York. Founded in 1988 by Leonard Schleifer and George Yancopoulos, Regeneron developed its own proprietary drug discovery technology platform (VelociGene, VelocImmune) that has enabled the development of multiple breakthrough medicines. The company reported revenues of $13.9B in FY2024, up 7% year-over-year.
Business Model & Competitive Advantage
Regeneron's commercial portfolio is led by Dupixent (dupilumab) — a monoclonal antibody targeting IL-4 and IL-13 for atopic dermatitis, asthma, chronic rhinosinusitis with nasal polyps, eosinophilic esophagitis, and other allergic/inflammatory conditions. Dupixent has become one of the fastest-growing drugs in pharmaceutical history, with global sales exceeding $14B annually and ongoing label expansion into new indications. Other key products include Eylea (aflibercept) for macular degeneration and diabetic eye disease, Praluent (alirocumab) for high cholesterol, Kevzara (sarilumab) for rheumatoid arthritis, and Libtayo (cemiplimab) for certain skin and lung cancers.
Competitive Landscape 2025–2026
Regeneron trades on NASDAQ (REGN) with a market cap of approximately $55–70B. The company has one of the most productive R&D organizations in biotech — its VelociSuite technology enables rapid antibody and bispecific generation. In 2024, the FDA approved a Dupixent biosimilar competition timeline, creating a long-term revenue headwind that Regeneron is offsetting through new indications and pipeline development including Dupixent for COPD, oncology bispecifics, and obesity programs.
Recent Activity
View all →Key Differentiators
Market Leader
Regeneron Pharmaceuticals is recognized as a market leader in the Healthcare Tech sector, demonstrating strong industry presence and customer trust.
Enterprise Scale
With $13.9B in revenue, Regeneron Pharmaceuticals operates at enterprise scale with proven market validation.
Frequently Asked Questions
Estimated Visibility Trend (Beta)
Simulated 8-week rolling score
Based on estimated brand signals. Historical tracking coming soon.
Similar Brands
Pfizer
Pfizer is one of the world's largest biopharmaceutical companies, founded in 1849 by cousins Charles Pfizer and Charles Erhart in Brooklyn, New York, and now headquartered in New York City. The compan
Moderna
Moderna is a clinical-stage biotechnology company that pioneered the development of messenger RNA (mRNA) therapeutics and vaccines, founded in 2010 by Noubar Afeyan, Robert Langer, Kenneth Chien, Stép
Amgen
Amgen Inc. is one of the world's largest biotechnology companies, headquartered in Thousand Oaks, California. Founded in 1980 as Applied Molecular Genetics, Amgen pioneered the development of biologic
Veeva Systems
Veeva Systems Inc. is the leading cloud software provider for the global life sciences industry, headquartered in Pleasanton, California. Founded in 2007 by Peter Gassner (a former Salesforce executiv
Doximity
Doximity is a professional network and digital health platform purpose-built for licensed physicians and other healthcare professionals in the United States. With more than two million verified clinic
Zocdoc
Zocdoc operates a two-sided marketplace connecting patients with physicians, dentists, and mental health providers who accept their specific insurance and have real-time appointment availability. Pati
Compare Regeneron Pharmaceuticals with Competitors
Side-by-side AI visibility scores, platform breakdown, and market position.
Claim This Profile
Are you from Regeneron Pharmaceuticals? Claim your profile to see full AI mention excerpts, get weekly visibility change alerts, and optimize how AI systems describe your brand.
Claim Regeneron Pharmaceuticals Profile →Track AI Visibility in Real Time
Monitor how ChatGPT, Gemini, Perplexity, and Claude mention Regeneron Pharmaceuticals vs competitors. Get alerts when AI recommendations shift.
Start Free Tracking →